Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. Issue 1 (24th May 2020)

• Record Type: Journal Article
• Authors: McGovern, Andrew P; Hogg, Michael; Shields, Beverley M; Sattar, Naveed A; Holman, Rury R; Pearson, Ewan R; Hattersley, Andrew T; Jones, Angus G; Dennis, John M
• Other Names: author non-byline.; Henley William E author non-byline.; Lonergan Mike author non-byline.; Rodgers Lauren R author non-byline.; Hamilton Willie T author non-byline.; Angwin Catherine author non-byline.; Cruickshank Kennedy J author non-byline.; Farmer Andrew J author non-byline.; Gough Stephen C L author non-byline.; Gray Alastair M author non-byline.; Hyde Christopher author non-byline.; Jennison Christopher author non-byline.; Walker Mark author non-byline.
• Is Part Of: BMJ open diabetes research and care. Volume 8:Issue 1(2020)
• Publication Date: 2020-05-24
• Subjects: non-insulin treated type 2 diabetes -- candida -- A1C -- adherence to medications; Diabetes -- Periodicals; 616.462005
• DOI: 10.1136/bmjdrc-2020-001238
• Languages: English
• ISSNs: 2052-4897

Abstract

Abstract : Introduction: To identify risk factors, absolute risk, and impact on treatment discontinuation of genital infections with sodium-glucose co-transporter-2 inhibitors (SGLT2i). Research design and methods: We assessed the relationship between baseline characteristics and genital infection in 21 004 people with type 2 diabetes initiating SGLT2i and 55 471 controls initiating dipeptidyl peptidase-4 inhibitors (DPP4i) in a UK primary care database. We assessed absolute risk of infection in those with key risk factors and the association between early genital infection and treatment discontinuation. Results: Genital infection was substantially more common in those treated with SGLT2i (8.1% within 1 year) than DPP4i (1.8%). Key predictors of infection with SGLT2i were female sex (HR 3.64; 95% CI 3.23 to 4.11) and history of genital infection; <1 year before initiation (HR 4.38; 3.73 to 5.13), 1–5 years (HR 3.04; 2.64 to 3.51), and >5 years (HR 1.79; 1.55 to 2.07). Baseline HbA1c was not associated with infection risk for SGLT2i, in contrast to DPP4i where risk increased with higher HbA1c . One-year absolute risk of genital infection with SGLT2i was highest for those with a history of prior infection (females 23.7%, males 12.1%), compared with those without (females 10.8%, males 2.7%). Early genital infection was associated with a similar discontinuation risk for SGLT2i (HR 1.48; 1.21–1.80) and DPP4i (HR 1.58; 1.21–2.07). Conclusions: Female sex and history of prior infection are simple features that can identify subgroups at greatly increased risk of genital infections with SGLT2i therapy. These data can be used to risk-stratify patients. High HbA1c is not a risk factor for genital infections with SGLT2i.